7.93
+0.01
+(0.13%)
At close: January 30 at 4:00:01 PM EST
7.12
-0.81
(-10.21%)
Pre-Market: 4:04:21 AM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-73,240.00
-63,847.00
-54,601.00
-32,410.00
-24,321.00
Investing Cash Flow
-50,994.00
-113,963.00
-67,869.00
-2,125.00
-771.00
Financing Cash Flow
94,037.00
97,290.00
95,629.00
166,259.00
10,036.00
End Cash Position
26,175.00
41,850.00
122,370.00
149,211.00
17,487.00
Capital Expenditure
-1,271.00
-709.00
-1,094.00
-2,125.00
-771.00
Issuance of Capital Stock
92,616.00
95,786.00
95,199.00
165,925.00
9,907.00
Repayment of Debt
--
--
--
--
-34.00
Free Cash Flow
-74,511.00
-64,556.00
-55,695.00
-34,535.00
-25,092.00
12/31/2020 - 10/29/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
TRDA Entrada Therapeutics, Inc.
13.37
+0.83%
CGEM Cullinan Therapeutics, Inc.
10.98
-2.40%
TNGX Tango Therapeutics, Inc.
3.1100
0.00%
IMCR Immunocore Holdings plc
32.61
+3.07%
IMTX Immatics N.V.
5.40
+1.31%
MOLN Molecular Partners AG
5.23
+0.19%
MBX MBX Biosciences, Inc.
11.64
+13.34%
NAMS NewAmsterdam Pharma Company N.V.
21.77
+4.76%
REPL Replimune Group, Inc.
13.62
-3.20%
RCUS Arcus Biosciences, Inc.
13.38
+2.84%